ImageneBio (NASDAQ:IMA – Get Free Report) issued its earnings results on Thursday. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.25), FiscalAI reports.
ImageneBio Stock Down 10.5%
NASDAQ IMA traded down $0.62 on Friday, reaching $5.29. The company had a trading volume of 75,284 shares, compared to its average volume of 1,023,482. The stock has a market capitalization of $56.34 million, a P/E ratio of -0.66 and a beta of 0.73. The company’s fifty day moving average is $5.71 and its 200 day moving average is $6.60. ImageneBio has a 52-week low of $3.94 and a 52-week high of $18.00.
Analysts Set New Price Targets
Separately, Wall Street Zen cut ImageneBio from a “hold” rating to a “sell” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $26.50.
Institutional Investors Weigh In On ImageneBio
A number of institutional investors and hedge funds have recently bought and sold shares of IMA. Goldman Sachs Group Inc. raised its position in ImageneBio by 62.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock valued at $98,000 after buying an additional 29,369 shares during the last quarter. Vanguard Group Inc. purchased a new stake in ImageneBio in the 3rd quarter valued at $1,902,000. BML Capital Management LLC purchased a new stake in ImageneBio in the 3rd quarter valued at $1,487,000. Aldebaran Capital LLC purchased a new stake in ImageneBio in the 3rd quarter valued at $159,000. Finally, Blue Owl Capital Holdings LP purchased a new stake in ImageneBio in the 3rd quarter valued at $4,409,000. 75.00% of the stock is owned by hedge funds and other institutional investors.
About ImageneBio
ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.
See Also
- Five stocks we like better than ImageneBio
- Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due
- Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches
- Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money
- Water Infrastructure: Why This Boring Sector Could Get Exciting
Receive News & Ratings for ImageneBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImageneBio and related companies with MarketBeat.com's FREE daily email newsletter.
